As he has done for years, President Donald Trump claims – without evidence – that the federal Right to Try law he signed in 2018 has “saved thousands of lives.” But the White House provided no support for Trump’s claim about the law, which provides an alternative route for seriously ill patients to access unapproved drugs outside of clinical trials.
Researchers who have long studied access to investigational drugs say the president is greatly exaggerating.
“It’s not that nobody is using Right to Try. There have been a handful of reported cases,” Holly Fernandez Lynch, associate professor of medical ethics at the University of Pennsylvania Perelman School of Medicine, told us in an interview. “But certainly it has not been thousands of patients … who’ve received drug therapy, let alone had their lives saved by these products.”
Alison Bateman-House, co-chair of NYU Grossman School of Medicine’s Working Group on Compassionate Use & Preapproval Access, said in an interview that Trump’s claim about the law saving thousands of lives is a “gross misestimate.”
Dr. Jeffrey A. Singer, a senior fellow at the libertarian Cato Institute who said he supported passage of the 2018 federal law, now says that it “fail[ed].” In a May opinion piece for Reason magazine, Singer argues for changes to the Right to Try law, writing that the promise of a right to try potential life-saving drugs “often exists more on paper than in practice.”
Reason, May 12: The sales pitch was sweeping. When President Donald Trump signed Right to Try in 2018, surrounded by patients, he promised a “fundamental freedom” that would give dying patients hope.
Eight years later, the record is far thinner than the rhetoric. The [Food and Drug Administration] reports only a handful of uses each year—12 drugs from 2018 to 2022, and just a few more annually since. It wasn’t a new pathway so much as a permission slip that rarely translates into access.




.jpg)












